Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. (Q40272558)
Jump to navigation
Jump to search
scientific article published on June 2006
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. |
scientific article published on June 2006 |
Statements
Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor (English)
Ana S Martins
Carlos Mackintosh
David Herrero Martín
Maria Campos
Teresa Hernández
Jose-Luis Ordóñez